Linked Life Data

17637682

Source:http://linkedlifedata.com/resource/pubmed/id/17637682

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17637682rdf:typepubmed:Citationlld:pubmed
pubmed-article:17637682lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C1708063lld:lifeskim
pubmed-article:17637682lifeskim:mentionsumls-concept:C1446539lld:lifeskim
pubmed-article:17637682pubmed:issue3lld:pubmed
pubmed-article:17637682pubmed:dateCreated2007-8-1lld:pubmed
pubmed-article:17637682pubmed:abstractTextThis phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur-uracil (UFT) with leucovorin (LV) combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal cancer (mCRC). Patients received oral UFT 250 mg m(-2) day(-1) and LV 90 mg day(-1) in three divided daily doses for 14 days followed by a 1-week rest and i.v. irinotecan 250 mg m(-2) as a 90-min infusion every 3 weeks. Tumour responses, assessed every two cycles using RECIST criteria, were reviewed by an independent review committee. In 52 evaluable patients, the best overall response rate was 33% (95% confidence intervals (CI) 20-47%; 1 complete and 16 partial responses). The median time to progression was 5.4 months (95% CI 3.02-7.52 months) and median overall survival was 14.9 months (11.73-17.97 months). A total of 307 cycles were administered, with a median number of five cycles per patient (range: 1-10). The most common grade 3/4 toxicities were neutropenia (25% of patients), diarrhoea (22%), vomiting (11%) and anaemia (11%). The TEGAFIRI regimen is a feasible, well-tolerated and convenient treatment option for patients with non-resectable mCRC.lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:languageenglld:pubmed
pubmed-article:17637682pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:citationSubsetIMlld:pubmed
pubmed-article:17637682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17637682pubmed:statusMEDLINElld:pubmed
pubmed-article:17637682pubmed:monthAuglld:pubmed
pubmed-article:17637682pubmed:issn0007-0920lld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:PerrierHHlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:SmithDDlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:BugatRRlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:PiedboisPPlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:NamanHHlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:DouillardJ...lld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:FrançoisEElld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:DesseigneFFlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:FarouxRRlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:ArtruPPlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:HusseiniFFlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:BennounaJJlld:pubmed
pubmed-article:17637682pubmed:authorpubmed-author:DelordJ-PJPlld:pubmed
pubmed-article:17637682pubmed:issnTypePrintlld:pubmed
pubmed-article:17637682pubmed:day6lld:pubmed
pubmed-article:17637682pubmed:volume97lld:pubmed
pubmed-article:17637682pubmed:ownerNLMlld:pubmed
pubmed-article:17637682pubmed:authorsCompleteYlld:pubmed
pubmed-article:17637682pubmed:pagination297-301lld:pubmed
pubmed-article:17637682pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:meshHeadingpubmed-meshheading:17637682...lld:pubmed
pubmed-article:17637682pubmed:year2007lld:pubmed
pubmed-article:17637682pubmed:articleTitlePhase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.lld:pubmed
pubmed-article:17637682pubmed:affiliationInstitut Claudius Regaud, 20-24 rue du Pont saint Pierre, Toulouse 31052, France. delord.jean-pierre@claudiusregaud.frlld:pubmed
pubmed-article:17637682pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17637682pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17637682lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17637682lld:pubmed